Drugs / IW-3300
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05362695 | May → Jun 2022 | — | Ironwood Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05188261 | Jan → Mar 2022 | — | Ironwood Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05740007 | Mar 2023 → Jan 2025 | interstitial cystitis | Ironwood Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-05-25 | Ironwood Pharmaceuticals, Inc. | Results Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022 ironwoodpharma.com ↗
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented new findings during the 2022 Digestive Disease Week ® (DDW) meeting that suggest colonic IW-3300 has the potential to help manage abdominopelvic visceral pain in patients with disorders of gut-brain interaction (DGBI) and related visceral pain disorders. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-05-25 | Ironwood Pharmaceuticals, Inc. | Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022 ironwoodpharma.com ↗ |
| 2022-05-09 | Ironwood Pharmaceuticals, Inc. | Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022 ironwoodpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IW-3300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05362695 ↗ |
| Route | Rectal | “administered rectally” NCT05188261 ↗ |